A detailed history of Ensign Peak Advisors, Inc transactions in Altimmune, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 326,777 shares of ALT stock, worth $2.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
326,777
Previous 326,777 -0.0%
Holding current value
$2.7 Million
Previous $2.17 Million 7.69%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $973,596 - $3.91 Million
232,362 Added 246.11%
326,777 $1.38 Million
Q4 2022

Feb 13, 2023

BUY
$8.74 - $16.45 $324,385 - $610,541
37,115 Added 64.77%
94,415 $1.55 Million
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $611,391 - $1.28 Million
57,300 New
57,300 $732,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $404M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.